Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Design, Synthesis, Pharmacological Evaluation and Vascular Effects of Delphinidin Analogues

Author(s): Samuel Legeay*, Kien Trân, Yannick Abatuci, Hélène Justiniano, Claire Lugnier, Olivier Duval, Jean-Jacques Helesbeux and Sébastien Faure

Volume 24, Issue 46, 2018

Page: [5580 - 5589] Pages: 10

DOI: 10.2174/1381612825666190206144913

Price: $65

Abstract

Background: Among polyphenolic compounds suggested to prevent cardiovascular diseases (CVDs) and to explain the “French paradox”, the anthocyanidin delphinidin (Dp) has been reported to support at least partly the vascular beneficial effects of dietary polyphenolic compounds including those from fruits and related products as red wine. It has also been highlighted that Dp interacts directly with the active site of estrogen receptor α (ERα), leading to activation of endothelial NO synthase (eNOS) pathway thus contributing to the prevention of endothelial dysfunction in mice aorta. However, anthocyanidins have very low bioavailability and despite a well described in vitro efficacy, the very high hydrophilicity and physicochemical instability of Dp might explain the lack of in vivo reported effects.

Objective: The aim of this study was to identify new Dp analogues with increased lipophilicity and vasorelaxation potential by a chemical modulation of its structure and to characterize the signaling pathway notably in relation with ERα signaling and nitric oxide (NO) production.

Method: OCH3-substituted delphinidin analogues were obtained through the coupling of the corresponding acetophenones with substituted benzaldehydes. Prediction of resorption of the flavylium derivatives was performed with the calculated logP and induction of vasorelaxation was performed by myography on WT and ERαKO mice thoracic aorta rings and compared to Dp. NO production was evaluated in vitro on human primary endothelial cells.

Results: Eight Dp analogues were synthesized including four new flavylium derivatives. Two compounds (9 and 11) showed a strong increase of vasorelaxation potential and a theoretically increased bioavailability compared to Dp. Interestingly, 9 and 11 induced increased O2 - or NO endothelial production respectively and revealed a novel NO-dependent ERα-independent relaxation compared to Dp. We suggested that this mechanism may be at least in part supported by the inhibition of vascular cyclic nucleotide phosphodiesterase (PDEs).

Conclusion: The current study demonstrated that pharmacomodulation of the Dp backbone by replacement of OH groups by OCH3 groups of the A and B rings led to the identification and characterization of two compounds (9 and 11) with enhanced physio-chemical properties that could be associated to higher permeability capability and pharmacological activity for the prevention of CVDs compared to Dp.

Keywords: Anthocyanidin, vasorelaxation, nitrite oxide, estrogen receptor α pathway, phosphodiesterase inhibition, structure-activity relationships.

« Previous Next »
[1]
WHO | Cardiovascular diseases (CVDs) [Internet]. WHO. [cited 2017 Sep 20]. Available from: http://www.who.int/ mediacentre/factsheets/fs317/en/
[2]
Woollard KJ. Immunological aspects of atherosclerosis Clin Sci Lond Engl 1979 . 2013. 125(5): 221-35
[3]
Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.”. Semin Thromb Hemost 2010; 36(1): 59-70.
[4]
Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet Lond Engl 1992; 339(8808): 1523-6.
[5]
Renaud SC, Guéguen R, Conard P, Lanzmann-Petithory D, Orgogozo J-M, Henry O. Moderate wine drinkers have lower hypertension-related mortality: a prospective cohort study in French men. Am J Clin Nutr 2004; 80(3): 621-5.
[6]
McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012; 95(2): 454-64.
[7]
Sarr M, Chataigneau M, Martins S, et al. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res 2006; 71(4): 794-802.
[8]
Agouni A, Lagrue-Lak-Hal A-H, Mostefai HA, et al. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PLoS One 2009; 4(5): e5557.
[9]
Andriambeloson E, Kleschyov AL, Muller B, Beretz A, Stoclet JC, Andriantsitohaina R. Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta. Br J Pharmacol 1997; 120(6): 1053-8.
[10]
Andriambeloson E, Magnier C, Haan-Archipoff G, et al. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. J Nutr 1998; 128(12): 2324-33.
[11]
Duarte J, Andriambeloson E, Diebolt M, Andriantsitohaina R. Wine polyphenols stimulate superoxide anion production to promote calcium signaling and endothelial-dependent vasodilatation. Physiol Res 2004; 53(6): 595-602.
[12]
Ndiaye M, Chataigneau T, Andriantsitohaina R, Stoclet J-C, Schini-Kerth VB. Red wine polyphenols cause endothelium-dependent EDHF-mediated relaxations in porcine coronary arteries via a redox-sensitive mechanism. Biochem Biophys Res Commun 2003; 310(2): 371-7.
[13]
Martin S, Andriambeloson E, Takeda K, Andriantsitohaina R. Red wine polyphenols increase calcium in bovine aortic endothelial cells: a basis to elucidate signalling pathways leading to nitric oxide production. Br J Pharmacol 2002; 135(6): 1579-87.
[14]
Chalopin M, Tesse A, Martínez MC, Rognan D, Arnal J-F, Andriantsitohaina R. Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PLoS One 2010; 5(1): e8554.
[15]
Lazzè MC, Pizzala R, Perucca P, et al. Anthocyanidins decrease endothelin-1 production and increase endothelial nitric oxide synthase in human endothelial cells. Mol Nutr Food Res 2006; 50(1): 44-51.
[16]
Keravis T, Favot L, Abusnina AA, et al. Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells. PLoS One 2015; 10(12): e0145291.
[17]
Abusnina A, Lugnier C. Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. Cell Signal 2017; 39: 55-65.
[18]
Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81(1)(Suppl.): 230S-42S.
[19]
Domitrovic R. The molecular basis for the pharmacological activity of anthocyans. Curr Med Chem 2011; 18(29): 4454-69.
[20]
Loypimai P, Moongngarm A, Chottanom P. Thermal and pH degradation kinetics of anthocyanins in natural food colorant prepared from black rice bran. J Food Sci Technol 2016; 53(1): 461-70.
[21]
Fleschhut J, Kratzer F, Rechkemmer G, Kulling SE. Stability and biotransformation of various dietary anthocyanins in vitro. Eur J Nutr 2006; 45(1): 7-18.
[22]
Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. 2nd ed. Londres: Lavoisier 1999. 1136 p 1136 p
[23]
Chassaing S. Rapid Preparation of 3-Deoxyanthocyanidins and Novel Dicationic Derivatives: New Insight into an Old Procedure.Eur J Org Chem [Internet]. [cited 2017 Sep 20]; Available from: http://www.academia.edu/34034469/Rapid_Preparation_of_3-Deoxyanthocyanidins_and_Novel_Dicationic_Derivatives_New_Insight_into_an_Old_Procedure
[24]
Selenski C, Pettus TRR. (±)-Diinsininone: made nature’s way. Tetrahedron 2006; 62(22): 5298-307.
[25]
Mas T. A New and Convenient One-StepSynthesis of the Natural 3-Deoxyanthocyanidins Apigeninidinand Luteolinidin Chlorides from 2,4,6-Triacetoxybenzaldehyde. Synthesis 2003; 2003(12): 1878-80.
[26]
Schmidt B, Riemer M. Synthesis of Allyl- and Prenylcoumarins via Microwave-Promoted Tandem Claisen Rearrangement/Wittig Olefination. Synthesis 2016; 48(01): 141-9.
[27]
Dong Y, Du N, Li X, Zheng L, Liu G. Tandem Chloropalladation/Cyclization and Dearomative Cyclization toward Functionalized Tricyclic Bridged [3.2.1] Skeleton Compounds. Org Lett 2015; 17(16): 4110-3.
[28]
Gudipudi G, Sagurthi SR, Perugu S, Achaiah G, Krupadanam GLD. Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent. RSC Advances 2014; 4(99): 56489-501.
[29]
Kraus M, Biskup E, Richling E, Schreier P. Synthesis of [4-14C]-pelargonidin chloride and [4-14C]-delphinidin chloride. J Labelled Comp Radiopharm 2006; 49(13): 1151-62.
[30]
Lan W, Lu F, Regner M, et al. Tricin, a flavonoid monomer in monocot lignification. Plant Physiol 2015; 167(4): 1284-95.
[31]
de Lassauniere P-EC, Harnett J, Bigg D, et al. Derivatives of heterocycles with 5 members, their preparation and their use as medicaments [Internet]. US20050038087 A1, 2005 [cited 2017 Sep 20]. Available from: http://www.google.com.pg/patents/US20050038087
[32]
Kuhnert N, Clifford MN, Radenac A-G. Boron trifluoride-etherate mediated synthesis of 3-desoxyanthocyanidins including a total synthesis of tricetanidin from black tea. Tetrahedron Lett 2001; 42(52): 9261-3.
[33]
Sousa A, Mateus N, de Freitas V. A novel reaction mechanism for the formation of deoxyanthocyanidins. Tetrahedron Lett 2012; 53(10): 1300-3.
[34]
Tetko IV, Gasteiger J, Todeschini R, et al. Virtual computational chemistry laboratory--design and description. J Comput Aided Mol Des 2005; 19(6): 453-63.
[35]
Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35(10): 1743-51.
[36]
Kameni Tcheudji JF, Lebeau L, Virmaux N, et al. Molecular organization of bovine rod cGMP-phosphodiesterase 6. J Mol Biol 2001; 310(4): 781-91.
[37]
Keravis T, Thaseldar-Roumié R, Lugnier C. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol BiolClifton NJ 2005; 307: 63-74.
[38]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[39]
Yi W, Akoh CC, Fischer J, Krewer G. Absorption of anthocyanins from blueberry extracts by caco-2 human intestinal cell monolayers. J Agric Food Chem 2006; 54(15): 5651-8.
[40]
Barcena HS, Chen P, Tuachi A. Synthetic anthocyanidins and their antioxidant properties. Springerplus 2015; 4: 499.
[41]
Gabetta BD, Giorgi RD. Intermediates useful for the synthesis of delphinidin chloride [Internet]. EP0390496 B1, 1994 [cited 2017 Mar 30]. Available from: http://www.google.com/patents/EP0390496B1
[42]
Chan S, Yan C. PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol 2011 Dec; 11(6): 720-4.
[43]
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014; 13(4): 290-314.
[44]
Lugnier C. PDE inhibitors: a new approach to treat metabolic syndrome? Curr Opin Pharmacol 2011; 11(6): 698-706.
[45]
Lugnier C, Keravis T, Eckly-Michel A. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. J Physiol Pharmacol Off J Pol Physiol Soc 1999; 50(4): 639-52.
[46]
Kessler T, Lugnier C. Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Eur J Pharmacol 1995; 290(2): 163-7.
[47]
Liu G, Sun X, Dai Y, et al. Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. J Sex Med 2010; 7(12): 3868-78.

Rights & Permissions Print Cite
Article Metrics
26
8
1
1
© 2024 Bentham Science Publishers | Privacy Policy